ATE346044T1 - Bicyclische benzamidverbindungen als für die behandlung neurologischer krankheiten geeignete histamin-h3-rezeptorliganden - Google Patents
Bicyclische benzamidverbindungen als für die behandlung neurologischer krankheiten geeignete histamin-h3-rezeptorligandenInfo
- Publication number
- ATE346044T1 ATE346044T1 AT03769430T AT03769430T ATE346044T1 AT E346044 T1 ATE346044 T1 AT E346044T1 AT 03769430 T AT03769430 T AT 03769430T AT 03769430 T AT03769430 T AT 03769430T AT E346044 T1 ATE346044 T1 AT E346044T1
- Authority
- AT
- Austria
- Prior art keywords
- histamine
- treatment
- receptor ligands
- neurological diseases
- benzamide compounds
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical class NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 1
- 102000004384 Histamine H3 receptors Human genes 0.000 title 1
- 108090000981 Histamine H3 receptors Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0224557.9A GB0224557D0 (en) | 2002-10-22 | 2002-10-22 | Novel compounds |
| GBGB0306328.6A GB0306328D0 (en) | 2002-10-22 | 2003-03-19 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE346044T1 true ATE346044T1 (de) | 2006-12-15 |
Family
ID=32178875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03769430T ATE346044T1 (de) | 2002-10-22 | 2003-10-20 | Bicyclische benzamidverbindungen als für die behandlung neurologischer krankheiten geeignete histamin-h3-rezeptorliganden |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7446103B2 (de) |
| EP (1) | EP1554243B1 (de) |
| JP (1) | JP2006505623A (de) |
| AR (1) | AR041672A1 (de) |
| AT (1) | ATE346044T1 (de) |
| AU (1) | AU2003278119A1 (de) |
| DE (1) | DE60309913T2 (de) |
| ES (1) | ES2276125T3 (de) |
| GB (2) | GB0224557D0 (de) |
| TW (1) | TW200418839A (de) |
| WO (1) | WO2004037788A1 (de) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000079D0 (en) | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| JP4292402B2 (ja) * | 2001-09-07 | 2009-07-08 | 小野薬品工業株式会社 | インドール誘導体化合物、それらの製造方法およびそれらを有効成分として含有する薬剤 |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| ATE441417T1 (de) | 2002-12-20 | 2009-09-15 | Glaxo Group Ltd | Benzoädüazepinderivate für die behandlung von neurologischen krankheiten |
| MXPA05013364A (es) | 2003-06-17 | 2006-03-17 | Arena Pharm Inc | Procedimiento para preparar 3-benzazepinas. |
| CA2566526C (en) * | 2004-06-02 | 2012-10-23 | F. Hoffmann-La Roche Ag | Naphthaline derivatives useful as histamine-3-receptor ligands |
| EP1771169A1 (de) | 2004-07-14 | 2007-04-11 | PTC Therapeutics, Inc. | Verfahren zur behandlung von hepatitis c |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| AU2005274927B2 (en) | 2004-07-15 | 2011-11-03 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| EP1632494A1 (de) * | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonisten |
| BRPI0519726B8 (pt) | 2004-12-21 | 2021-05-25 | Arena Pharm Inc | composto de hemidrato de (r)-8-cloro-1-metil-2,3,4,5-tetraidro-1h-3-benzazepina, composição compreendendo o referido composto e seus usos |
| BRPI0515862A2 (pt) | 2004-12-23 | 2011-10-11 | Arena Pharm Inc | uso de fentermina e agonista seletivo do receptor de 5ht-2c na preparação de composições, composições moduladoras do receptor de 5ht-2c e forma de dosagem unitária compreendendo as mesmas |
| EP1717235A3 (de) * | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidine und -pyrrolidine und ihre Verwendung als Liganden für den Histamin H3-Rezeptor |
| EP1717234A1 (de) * | 2005-04-29 | 2006-11-02 | Bioprojet | Phenoxypropylpiperidine und -pyrrolidine und ihre Verwendung als Liganden für den Histamin H3-Rezeptor |
| WO2007050124A1 (en) * | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
| GB0513886D0 (en) | 2005-07-06 | 2005-08-10 | Glaxo Group Ltd | Novel compounds |
| KR101594898B1 (ko) | 2005-07-15 | 2016-02-18 | 알바니 몰레큘라 리써치, 인크. | 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
| AR056690A1 (es) * | 2005-10-14 | 2007-10-17 | Athersys Inc | Derivados de indol como inhibidores de indol como inhibidores del receptor 3 de histamina para el tartamiento de trastornos del sueno y cognitivos obesidad y otros trastornos de snc |
| JP5199997B2 (ja) | 2006-04-03 | 2013-05-15 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンズアゼピンおよびこれに関連する中間体を調製するためのプロセス |
| AU2007236052A1 (en) * | 2006-04-12 | 2007-10-18 | F. Hoffmann-La Roche Ag | 5-amido-2-carboxamide indoles |
| WO2007134149A2 (en) | 2006-05-11 | 2007-11-22 | Janssen Pharmaceutica N.V. | 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as cetp inhibitors |
| US7928238B2 (en) | 2006-05-11 | 2011-04-19 | Janssen Pharmaceutica Nv | 1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors |
| JP5404414B2 (ja) | 2006-12-05 | 2014-01-29 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンおよびその中間体を調製するための方法 |
| US7648979B2 (en) * | 2007-02-07 | 2010-01-19 | Hoffmann-La Roche Inc. | 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives |
| US7960567B2 (en) | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
| NZ580802A (en) | 2007-05-10 | 2012-09-28 | Albany Molecular Res Inc | Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| WO2009085177A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Phenyl acetic acid derivatives as inflammation modulators |
| US8822727B2 (en) | 2008-03-04 | 2014-09-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| EP2246331A1 (de) * | 2009-04-24 | 2010-11-03 | Westfälische Wilhelms-Universität Münster | NR2B-selektive NMDA-Rezeptorantagonisten |
| WO2010132487A1 (en) | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
| US8802696B2 (en) * | 2009-05-12 | 2014-08-12 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof |
| CN102458123A (zh) * | 2009-05-12 | 2012-05-16 | 阿尔巴尼分子研究公司 | 芳基、杂芳基和杂环取代的四氢异喹啉及其用途 |
| WO2010148207A2 (en) | 2009-06-18 | 2010-12-23 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-ht2c receptor agonists |
| EP2459529A1 (de) * | 2009-07-02 | 2012-06-06 | Cephalon, Inc. | Substituierte phenoxypropylcycloaminderivate als histamin-3 (h3) rezeptorliganden |
| EP2371808A1 (de) * | 2010-03-08 | 2011-10-05 | Ratiopharm GmbH | Verfahren zur Herstellung von Dronedaron |
| KR20130112848A (ko) | 2010-06-02 | 2013-10-14 | 아레나 파마슈티칼스, 인크. | 5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법 |
| EP3485878A1 (de) | 2010-09-01 | 2019-05-22 | Arena Pharmaceuticals, Inc. | Darreichungsformen von 5-ht2c-agonisten, die nützlich für gewichtskontrolle sind |
| US8999970B2 (en) | 2010-09-01 | 2015-04-07 | Arena Pharmaceuticals, Inc. | Administration of an anti-obesity compound to individuals with renal impairment |
| SG188361A1 (en) | 2010-09-01 | 2013-04-30 | Arena Pharm Inc | Non-hygroscopic salts of 5-ht2c agonists |
| KR20130138770A (ko) | 2010-09-01 | 2013-12-19 | 아레나 파마슈티칼스, 인크. | 광학적으로 활성 산을 갖는 로르카세린의 염 |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| EP2647377A1 (de) | 2012-04-06 | 2013-10-09 | Sanofi | Verwendung eines H3-Rezeptorantagonisten zur Behandlung von Morbus Alzheimer |
| CA2886875A1 (en) | 2012-10-09 | 2014-04-17 | Arena Pharmaceuticals, Inc. | Method of weight management |
| FR3008979B1 (fr) * | 2013-07-23 | 2015-07-24 | Servier Lab | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2015074081A1 (en) | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Benzopiperazine compositions as bet bromodomain inhibitors |
| PT3071203T (pt) | 2013-11-18 | 2021-03-11 | Forma Therapeutics Inc | Composições de tetra-hidroquinolina como inibidores de bromodomínio bet |
| AU2016341884B2 (en) | 2015-10-19 | 2021-06-10 | Board Of Regents, The University Of Texas System | Piperazinyl norbenzomorphan compounds and methods for using the same |
| CA3022512A1 (en) | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Sigma receptor binders |
| JP7696997B2 (ja) | 2020-08-14 | 2025-06-23 | ミネルヴァ ニューロサイエンシズ，インコーポレーテッド | シグマリガンド化合物としての縮合アザ環およびその使用 |
| WO2024216197A2 (en) * | 2023-04-13 | 2024-10-17 | Acelot, Inc. | Compounds and methods for treating protein aggregation diseases |
| CN119118902A (zh) * | 2024-09-09 | 2024-12-13 | 郑州药领医药科技有限公司 | 一种5，6-二甲氧基异吲哚啉盐酸盐的合成方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU614965B2 (en) * | 1987-06-06 | 1991-09-19 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Thiadiazinones |
| US5496844A (en) * | 1992-05-08 | 1996-03-05 | Otsuka Pharmaceutical Factory, Inc. | Indole derivatives |
| CA2192928C (en) | 1994-06-15 | 2010-10-26 | Hidenori Ogawa | Benzoheterocyclic derivatives |
| JPH09221476A (ja) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
| EP0973778A1 (de) | 1997-03-07 | 2000-01-26 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-derivate ihre herstellung und ihre verwendung |
| GB9708805D0 (en) | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
| PL336628A1 (en) | 1997-05-03 | 2000-07-03 | Smithkline Beecham Plc | Derivatives of tetrahydroisoquinoline as modulators of d3 dopamine receptors |
| EP0982300A3 (de) | 1998-07-29 | 2000-03-08 | Societe Civile Bioprojet | Alkylamine ohne Imidazolring als Histamin-H3-antagonisten und deren therapeutische Anwendung |
| HUP0202787A3 (en) * | 1999-09-25 | 2003-12-29 | Smithkline Beecham Plc | Piperazine derivatives as 5-ht1b antagonists, process for their preparation and pharmaceutical compositions containing them |
| WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
| US6743793B2 (en) | 2000-03-09 | 2004-06-01 | Ono Pharmaceutical Co., Ltd. | Indole derivatives, process for preparation of the same and use thereof |
| KR100852362B1 (ko) | 2000-08-08 | 2008-08-14 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 비-이미다졸 아릴옥시피페리딘 |
| US20030013733A1 (en) | 2000-09-22 | 2003-01-16 | Richard Apodaca | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine |
| WO2002076925A2 (en) | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| WO2002094788A1 (en) | 2001-05-22 | 2002-11-28 | Eli Lilly And Company | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods |
| MY140236A (en) | 2002-09-19 | 2009-12-31 | Lilly Co Eli | Diarylether compounds useful as opioid receptor antagonists |
| GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| GB0224083D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| EP1554260A1 (de) | 2002-10-22 | 2005-07-20 | Glaxo Group Limited | Aryloxyalkylamine derivate als h3 rezeptor liganden |
-
2002
- 2002-10-22 GB GBGB0224557.9A patent/GB0224557D0/en not_active Ceased
-
2003
- 2003-03-19 GB GBGB0306328.6A patent/GB0306328D0/en not_active Ceased
- 2003-10-20 TW TW092128958A patent/TW200418839A/zh unknown
- 2003-10-20 DE DE60309913T patent/DE60309913T2/de not_active Expired - Fee Related
- 2003-10-20 AR ARP030103815A patent/AR041672A1/es unknown
- 2003-10-20 AU AU2003278119A patent/AU2003278119A1/en not_active Abandoned
- 2003-10-20 EP EP03769430A patent/EP1554243B1/de not_active Expired - Lifetime
- 2003-10-20 JP JP2005501524A patent/JP2006505623A/ja active Pending
- 2003-10-20 AT AT03769430T patent/ATE346044T1/de not_active IP Right Cessation
- 2003-10-20 WO PCT/EP2003/011650 patent/WO2004037788A1/en not_active Ceased
- 2003-10-20 ES ES03769430T patent/ES2276125T3/es not_active Expired - Lifetime
- 2003-10-20 US US10/532,373 patent/US7446103B2/en not_active Expired - Fee Related
-
2008
- 2008-09-29 US US12/239,874 patent/US20090042862A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004037788A1 (en) | 2004-05-06 |
| DE60309913T2 (de) | 2007-06-28 |
| US20070105838A1 (en) | 2007-05-10 |
| US7446103B2 (en) | 2008-11-04 |
| GB0306328D0 (en) | 2003-04-23 |
| US20090042862A1 (en) | 2009-02-12 |
| GB0224557D0 (en) | 2002-11-27 |
| AU2003278119A1 (en) | 2004-05-13 |
| EP1554243B1 (de) | 2006-11-22 |
| ES2276125T3 (es) | 2007-06-16 |
| DE60309913D1 (de) | 2007-01-04 |
| EP1554243A1 (de) | 2005-07-20 |
| TW200418839A (en) | 2004-10-01 |
| AR041672A1 (es) | 2005-05-26 |
| JP2006505623A (ja) | 2006-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60309913D1 (de) | BICYCLISCHE BENZAMIDVERBINDUNGEN ALS FüR DIE BEHANDLUNG NEUROLOGISCHER KRANKHEITEN GEEIGNETE HISTAMIN-H3-REZEPTORLIGANDEN | |
| ATE374196T1 (de) | Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen | |
| DE60329123D1 (de) | Benzoädüazepinderivate für die behandlung von neurologischen krankheiten | |
| ATE551340T1 (de) | Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten | |
| DE602004022871D1 (de) | Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten | |
| DE60233414D1 (de) | Kombinationen für die behandlung entzündlicher erkrankungen | |
| DE602005007717D1 (de) | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen | |
| NO20052223D0 (no) | Tiazolforbindelser for behandling av neurodegenerative forstyrrelser | |
| IL164263A0 (en) | Use of ep4 receptor ligands on the treatment of il-6 involved diseases | |
| DE60230773D1 (de) | Harnstoff-derivate als vanilloid-rezeptor-antagonisten für die schmerzbehandlung | |
| ATE266655T1 (de) | Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit | |
| EP1501489A4 (de) | Kombinationstherapie zur behandlung von krebs | |
| EP1556047A4 (de) | Pgd2-rezeptor-antagonisten zur behandlungvon entz ndlichen erkrankungen | |
| EP1511508A4 (de) | Verfahren zur behandlung dyslipidämischer störungen | |
| ATE402165T1 (de) | Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten. | |
| EP1601251A4 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| ATE371451T1 (de) | Duale nk1/nk3 antagonisten zur behandlung von schizophrenie | |
| AU2003285091A8 (en) | Interferon antagonists useful for the treatment of interferon related diseases | |
| DE60309909D1 (de) | Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen | |
| ATE437861T1 (de) | 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen | |
| GB0329874D0 (en) | Compounds useful for the treatment of diseases | |
| EP1717235A3 (de) | Phenoxypropylpiperidine und -pyrrolidine und ihre Verwendung als Liganden für den Histamin H3-Rezeptor | |
| DE60305063D1 (de) | Ccr1-rezeptor-antagonisten zur behandlung u.a. demyelinisierender entzündlicher erkrankungen | |
| DE602004003914D1 (de) | Für die therapie geeignete triazolverbindungen | |
| ATE355283T1 (de) | Isochroman verbindungen für die behandlung von cns-krankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |